Mukherjee Rahul K, O'Neill Louisa, O'Neill Mark D
Division of Imaging Sciences and Biomedical Engineering, King's College London.
2. Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Arrhythm Electrophysiol Rev. 2017 Aug;6(3):125-128. doi: 10.15420/aer.2017:17:1.
Ventricular tachycardia (VT), often degenerating into ventricular fibrillation, is the leading cause of sudden cardiac death. Catheter ablation of VT is associated with relatively low, long-term success rates, while the optimal timing of ablation in patients with ischaemic and non-ischaemic cardiomyopathy remains unclear. Contemporary practice in most centres is to consider ablation late in the disease process following the failure of anti-arrhythmic medications and/or following recurrent implantable cardioverter-defibrillator shocks. Three major randomised, controlled trials have been published investigating the role of prophylactic catheter ablation for VT. In the present review, we assess the evidence from these and other related trials in VT ablation to understand if there is sufficient evidence to advocate prophylactic catheter ablation in patients with VT.
室性心动过速（VT）常恶化为心室颤动，是心源性猝死的主要原因。VT的导管消融术长期成功率相对较低，而缺血性和非缺血性心肌病患者的最佳消融时机仍不明确。大多数中心目前的做法是在抗心律失常药物治疗失败和/或植入式心律转复除颤器反复电击后，在疾病晚期考虑进行消融。已经发表了三项主要的随机对照试验，研究预防性导管消融对VT的作用。在本综述中，我们评估这些试验以及VT消融其他相关试验的证据，以了解是否有足够的证据支持对VT患者进行预防性导管消融。
